[Skip to Navigation]
March 10, 2021

Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco
JAMA Dermatol. 2021;157(4):381-383. doi:10.1001/jamadermatol.2020.5466

Hidradenitis suppurativa (HS) is a clinically heterogeneous disease with few effective treatments.1 While clinical examination forms the basis for HS diagnosis and evaluation, HS clinical heterogeneity poses substantial challenges for assessing disease severity, activity, and treatment response.2 Efforts to accurately quantify HS severity and treatment response have resulted in the development of more than 30 investigator- and patient-reported outcome measures, several of which are unvalidated and some of which are unresponsive to changes in disease, that have been used in more than 12 randomized clinical trials, thus limiting comparisons of evidence across trials.3

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words